SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Terra Tech Corp (OTCMKTS:TRTC) subsidiary unit MediFarm reported that they are going to start the construction of medical cannabis dispensary based in Las Vegas. It is located adjacent to the Las Vegas strip.

The certificate

 MediFarm acquired a provisional registration certificate from ‘Department of Health and Human Services’, Nevada in 2014. Later, Terra Tech’s subsidiary filed its Business License Application with Department of Planning Business Licensing in 2014. The Company projects all ongoing work will be ended soon and the facility will commence operations by October 2015.

The expert view

The CEO Derek Peterson expressed that Terra Tech have recorded considerable progress in Nevada till this time in 2015. They have associated with the leading builders and architects to complete multiple projects in the state. The retail dispensary in Las Vegas is slated to be the first location to commence its operations. It will act as anchor location within the State of Nevada. In addition, Terra Tech has been working together with other firms to secure superior quality cannabis products to fill store shelves for patients.

The plans

The CEO further said that their prime focus is on offering the premium quality experience to patients throughout Nevada. It is their top most goal and they will take all required measures to turn into a reality. The management is confident that the team’s expertise and the availability of advanced products for certain disorder and pairing strains will result in a distinct identity. Due to the high quality products and new approvals Terra Tech is set to get a competitive edge over its competitors. The company will continue to release update on their underway and planned projects in Nevada as and when the planned milestones are met.

On Thursday Terra Tech Corp (OTCMKTS:TRTC) extended its weekly losses and declined to close at $0.140. The company has a market cap of $30.08 million.